{"nctId":"NCT01975246","briefTitle":"Add-on to Micamlo BP Trial","startDateStruct":{"date":"2013-11"},"conditions":["Hypertension"],"count":309,"armGroups":[{"label":"Telmisartan+amlodipine+HCTZ","type":"EXPERIMENTAL","interventionNames":["Drug: Telmisartan + amlodipine","Drug: hydrochlorothiazide"]},{"label":"Telmisartan+amlodipine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Telmisartan + amlodipine","Drug: Placebo"]}],"interventions":[{"name":"Telmisartan + amlodipine","otherNames":[]},{"name":"hydrochlorothiazide","otherNames":[]},{"name":"Telmisartan + amlodipine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \\>=90 and \\<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\\<200 mmHg\n* Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion\n* Age 20 years or older\n\nExclusion criteria:\n\n* Patients with known or suspected secondary hypertension\n* Patients with clinically relevant cardiac arrhythmia\n* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV\n* Patients with recent cardiovascular events\n* Patients with recent stroke events\n* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy\n* Patients with hepatic and/or renal dysfunction\n* Pre-menopausal women who are nursing or pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.","description":"Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"0.5"},{"groupId":"OG001","value":"-4.5","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.","description":"Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.3","spread":"0.8"},{"groupId":"OG001","value":"-6.9","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period","description":"Patients with trough seated DBP =\\>90 mmHg or trough seated SBP \\>=140 mmHg at baseline were analysed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":149},"commonTop":["Blood uric acid increased","Nasopharyngitis","Hyperuricaemia"]}}}